SLN (Silence Therapeutics) FCF Margin % : -102.20% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Silence Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-24.86 Mil. Silence Therapeutics's Revenue for the three months ended in Dec. 2024 was $24.33 Mil. Therefore, Silence Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -102.20%.

As of today, Silence Therapeutics's current FCF Yield % is -56.07%.

The historical rank and industry rank for Silence Therapeutics's FCF Margin % or its related term are showing as below:

SLN' s FCF Margin % Range Over the Past 10 Years
Min: -60027.27 Med: -181.45 Max: 703.75
Current: -160

During the past 13 years, the highest FCF Margin % of Silence Therapeutics was 703.75%. The lowest was -60027.27%. And the median was -181.45%.

SLN's FCF Margin % is ranked worse than
53.02% of 1009 companies
in the Biotechnology industry
Industry Median: -128.43 vs SLN: -160.00

Silence Therapeutics FCF Margin % Historical Data

The historical data trend for Silence Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics FCF Margin % Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-206.05

44.08

-265.94

-156.49

-156.85

Silence Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-491.09	-60.41	-807.67	-1,780.56	-102.20

Competitive Comparison of Silence Therapeutics's FCF Margin %

For the Biotechnology subindustry, Silence Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Silence Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Silence Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-67.851	/	43.258
	=	-156.85 %

Silence Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-24.864	/	24.328
	=	-102.20 %

Silence Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.